Frédéric Pouliot

• Centre de recherche du CHU de Québec - Université Laval
• Centre de recherche sur le cancer

Financements des 2 dernières années

• Camille Lafront, Stage postdoctoral en médecine
• Jade St-Amour-Bédard, Maîtrise en épidémiologie - épidémiologie clinique - avec mémoire
• Jean-Baptiste Vergnes, Stage postdoctoral en médecine
• Mame Sokhna Sylla, Doctorat en médecine moléculaire
• Raphael Vincent, Maîtrise en médecine moléculaire - avec mémoire

Encadrements des 5 dernières années

• Imen Chebra, Doctorat en biologie cellulaire et moléculaire
• Lucas Germain, Doctorat en médecine moléculaire
• Mame Sokhna Sylla, Maîtrise en médecine moléculaire - avec mémoire
• Nawar Touma, Maîtrise en épidémiologie - épidémiologie clinique - avec mémoire
• Samuel Tremblay, Maîtrise en épidémiologie - épidémiologie clinique - avec mémoire
• Sébastien Le Batteux, Doctorat en microbiologie-immunologie

Travaux de recherche des 5 dernières années

PSMA-Targeted Radioligand Therapy for Androgen Pathway Modulation-Resistant Prostate Cancer (APMR) in the Chemotherapy-Naïve Setting: A Narrative Review and Expert Commentary Current Oncology, 2026. Di Maria Jiang, Kim N. Chi, Urban Emmenegger, Sebastien J. Hotte, Girish S. Kulkarni, Aly-Khan A. Lalani, Krista L. Noonan, Frédéric Pouliot, Ricardo A. Rendon, Christopher J. D. Wallis, Steven M. Yip, Fred Saad. DOI 10.3390/curroncol33110667

Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches Cancers, 2026. Zahra Khazaei, Frédéric Pouliot, Louis Archambault. DOI 10.3390/cancers18111751

ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer Cancers, 2026. Gabriel Boulay, Marwan Khodr, Ann-Charlotte Bergeron, Émilie Wong Chong, France-Hélène Joncas, Chloé Castonguay, Karine Robitaille, Hélène Hovington, Vincent Fradet, Alain Bergeron, Frédéric Pouliot, Jonatan Blais, Nabil G. Seidah, Frédéric Calon, Anne Gangloff. DOI 10.3390/cancers18071176

Outcomes and Predictors of Recurrence and Survival in Surgically Resected Localized Chromophobe Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCis) Current Oncology, 2026. Erica Arenovich, Rodney Breau, Ricardo Rendon, Ranjeeta Mallick, Simon Tanguay, Frederic Pouliot, Luke Lavallee, Andrew Feifer, Antonio Finelli, Rahul Bansal, Jean-Baptiste Lattouf, Miles Mannas, Bimal Bhindi, Jasmir G. Nayak, Naveen Basappa, Daniel Y. C. Heng, Aly-Khan A. Lalani, Georg Bjarnason, Lori Wood. DOI 10.3390/curroncol33030175

Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer Canadian Urological Association Journal, 2025. Christian Kollmannsberger, Antonio Finelli, Andrew Loblaw, Tamim Niazi, Frédéric Pouliot, Ricardo A. Rendon, Bobby Shayegan, Fred Saad. DOI 10.5489/cuaj.9100

Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients Cancers, 2025. Noa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, Camilla Tajzler, Lori A. Wood, Christian Kollmannsberger, Naveen S. Basappa, Jeffrey Graham, Nazanin Fallah-Rad, Daniel Y.C. Heng, Denis Soulières, Aly-Khan A. Lalani, Rodney H. Breau, Antonio Finelli, Simon Tanguay, Bimal Bhindi, Georg Bjarnason, Frederic Pouliot, Christina Canil. DOI 10.3390/cancers17030522

Response to the Letter to the Editor The Prostate, 2024. Nawar Touma, Frederic Pouliot. DOI 10.1002/pros.24783

Rediscovering citrate as a biomarker for prostate cancer Nature Reviews Urology, 2024. Lucas Galey, Ayokunle Olanrewaju, Hermann Nabi, Jean-Sébastien Paquette, Frédéric Pouliot, Étienne Audet-Walsh. DOI 10.1038/s41585-024-00899-3

Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database Current Oncology, 2024. Changsu Lawrence Park, Feras Ayman Moria, Sunita Ghosh, Lori Wood, Georg A. Bjarnason, Bimal Bhindi, Daniel Yick Chin Heng, Vincent Castonguay, Frederic Pouliot, Christian K. Kollmannsberger, Dominick Bosse, Naveen S. Basappa, Antonio Finelli, Nazanin Fallah-rad, Rodney H. Breau, Aly-Khan A. Lalani, Simon Tanguay, Jeffrey Graham, Ramy R. Saleh. DOI 10.3390/curroncol31080351

An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells Biosensors, 2024. Audrey Champagne, Imene Chebra, Pallavi Jain, Cassandra Ringuette Goulet, Annie Lauzier, Antoine Guyon, Bertrand Neveu, Frédéric Pouliot. DOI 10.3390/bios14040175

177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice Current Oncology, 2024. Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad. DOI 10.3390/curroncol31030106

Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now European Urology, 2023. Frédéric Pouliot, Louise Emmett. DOI 10.1016/j.eururo.2023.07.007

Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo Nature Reviews Urology, 2023. Lucas Germain, Camille Lafront, Virginie Paquette, Bertrand Neveu, Jean-Sébastien Paquette, Frédéric Pouliot, Étienne Audet-Walsh. DOI 10.1038/s41585-023-00726-1

Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy The Prostate, 2023. Jérémie Beck, Mélanie Rouleau, Francis Lemire, Bertrand Neveu, Michel Déry, Benoît Thériault, Gabriel Dubois, Dominique Guérette, Frédéric Pouliot. DOI 10.1002/pros.24501

Supplementary Appendix from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480893

Figure S1 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480902

Figure S2 from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480896.v1

Data from Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.c.6530550.v1

Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level Journal of Urology, 2022. Mélanie Rouleau, Bertrand Neveu, Patrick Caron, Fannie Morin, Paul Toren, Louis Lacombe, Véronique Turcotte, Éric Lévesque, Chantal Guillemette, Frédéric Pouliot. DOI 10.1097/JU.0000000000002923

Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. Clinical genitourinary cancer, 2022. DOI 10.1016/j.clgc.2021.11.018

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and translational medicine, 2022. DOI 10.1002/ctm2.581

Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. DOI 10.5489/cuaj.7760

Canadian Urological Association guideline: Management of small renal masses - Full-text. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. DOI 10.5489/cuaj.7763

A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy. Theranostics, 2022. DOI 10.7150/thno.63744

Ultrasound Correlates Highly with Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort. Urology, 2022. DOI 10.1016/j.urology.2022.02.020

PSMA-targeted imaging with F-18-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.15_suppl.5023

Bisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression. Cancers, 2021. DOI 10.3390/cancers13215461

PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.33

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7074

ULTRASOUND CORRELATES HIGHLY WITH CROSS SECTIONAL IMAGING FOR SMALL RENAL MASSES IN A CONTEMPORARY COHORT: RESULTS FROM THE CANADIAN KIDNEY CANCER COLLABORATION Journal of Urology, 2021.

The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. BJU international, 2021. DOI 10.1111/bju.15621

A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW) Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.TPS187

Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. Urology, 2021. DOI 10.1016/j.urology.2021.05.053

The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized? Urologic oncology, 2021. DOI 10.1016/j.urolonc.2021.05.026

Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner. Molecular & cellular proteomics : MCP, 2021. DOI 10.1016/j.mcpro.2021.100064

Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.6779

Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical genitourinary cancer, 2021. DOI 10.1016/j.clgc.2021.05.004

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). The Journal of urology, 2021. DOI 10.1097/JU.0000000000001698

Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7357

CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL Journal of Urology, 2021.

PSMA Theranostics: Current Landscape and Future Outlook. Cancers, 2021. DOI 10.3390/cancers13164023

Outcomes for patients in the pembrolizumab plus axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.327

Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7355

Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. European urology focus, 2021. DOI 10.1016/j.euf.2021.10.004

A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.32

Reply by Authors. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001230.03

Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001230

Achieving the "trifecta" with open versus minimally invasive partial nephrectomy. World journal of urology, 2021. DOI 10.1007/s00345-020-03349-y

Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.6833

Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical genitourinary cancer, 2021. DOI 10.1016/j.clgc.2021.12.003

Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. Urologic oncology, 2021. DOI 10.1016/j.urolonc.2021.08.016

Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7347

Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia, 2021. DOI 10.1111/anae.15458

TGFβ Signaling in the Tumor Microenvironment. Advances in experimental medicine and biology, 2021. DOI 10.1007/978-3-030-47189-7_6

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426 Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.15_suppl.4500

Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. Urologic oncology, 2021. DOI 10.1016/j.urolonc.2021.02.025

A Phase 3 study of F-18-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer (CONDOR): An Analysis of Disease Detection Rate and Positive Predictive Value (PPV) by Anatomic Region Journal of Nuclear Medicine, 2021.

18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7107

Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study. Anaesthesia, 2021. DOI 10.1111/anae.15560

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. DOI 10.1158/1078-0432.CCR-20-4573

Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001517

Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA. International journal of molecular sciences, 2021. DOI 10.3390/ijms22189757

A prospective phase 2/3 study of PSMA-targeted F-18-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.15_suppl.e17003